The disclosure relates to systems and methods for the storage and transportation of bodily tissue.
The current invention generally relates to devices, systems, and methods for extracorporeal preservation of bodily tissue. Extracorporeal preservation of bodily tissue is essential in transplant procedures so that donor tissue can be transported to a recipient in a remote location. In order to provide the best graft survival rates, donor tissues must be matched to appropriate recipients. Because of the sudden nature of most tissue donation events, appropriate recipients must be rapidly located and must be within a limited geographic area of the donor. Time limitations on the extracorporeal viability of donor tissue can lead to less than ideal tissue matching and, worse, wasted donor tissue. Prolonging the viability of donor tissue can allow for better matching between donor tissue and recipients and, in turn, can increase graft survival rates and increase availability of donor tissue to the growing waitlists of individuals in need of transplants.
The most prevalent current technique for preserving a bodily tissue for transplantation is static cold storage. While hypothermic temperatures decrease the oxygen demand of the bodily tissue, the tissue's viability is still time-limited by insufficient oxygen levels to meet the tissue's decreased metabolic needs. Another known technique for preserving a bodily tissue for transplantation includes the use of hypothermic perfusion devices that can perfuse the tissue with oxygenated perfusate, supplying additional oxygen to the tissue's cells and prolonging tissue viability. The portability of such known devices is limited, however, because such known devices are large and require a significant volume of compressed gas and electrical power. Furthermore, such known devices are very complex, which can lead to increased manufacturing costs and higher failure rates.
An additional limitation of hypothermic storage is the tendency to cause edema, or the accumulation of fluid within the bodily tissue. The level of edema generally increases with the length of hypothermic storage, providing another limitation on the amount of time that a tissue can be stored and remain viable.
Because of the time limitations on tissue viability, even given modern hypothermic storage and perfusion techniques, tissue and organs are often transported via air and, accordingly, subjected to pressure changes associated with changes in altitude.
Systems and methods of the invention are directed to increasing donor tissue viability during and after storage and transport. In particular, systems and methods relate to storage and transport of lungs. As noted above, tissue transported by air may be subjected to changes in pressure associated with increases and decreases in altitude during flight. While changes in pressure may affect any tissue being transported, they can be particularly harmful to lung tissue. In typical donor lung retrieval and preparation, the donor lung is inflated with air and the trachea or bronchus is stapled to hold the air in the partially inflated lung and to keep preservation fluid out of the airways during storage and transport. Unfortunately, this inflation occurs on the ground and, once subjected to decreases in air pressure from flights at high altitude, the pressure differential between the sealed lung airways and surrounding preservation fluid and air can result in over inflation of the lung and damage to the tissue including rupturing of the alveoli or other air passages. Accordingly systems and methods of the invention may be used to monitor and maintain a relatively constant pressure within donor lungs during transport and storage while maintaining a desired level of inflation. Systems and methods can accomplish those tasks while maintaining separation between the non-sterile airway environment and the sterilized outer tissue surfaces and preservation fluid to help prevent infection of the donor tissue or the transplant recipient. Expandable accumulators of the invention may have variable volume and may include a gauge to indicate the volume of the accumulator. In certain embodiments, the accumulator may be filled to a volume based on the atmospheric pressure at the recovery site in order to compensate for various ambient pressures based on altitude or weather conditions in different locations. Methods may include adjusting the volume of the accumulator based on the ambient pressure at the recovery site before organ transport.
In certain embodiments, an expandable accumulator is coupled to the airways of the donor lung(s) and sealed in fluid communication therewith. The expandable accumulator may be more compliant than the airways of the donor lung such that the expandable accumulator expands in response to a relative increase in the volume of gas (e.g., through a change in relative pressure) contained in the closed system formed by the lungs airways and accumulator. By expanding, the accumulator can accommodate and absorb the relative increases in gas volume, stabilizing pressure within the system, and preventing over-inflation of and damage to the lung tissue.
Another drawback of current lung transport techniques is that lungs are typically transported horizontally on a flat surface or on a bed of crushed ice. Both techniques are far different from the geometry and orientation of the lung's anatomical home. By resting the lung horizontally, gravity can crush or damage the bottom-most airways. A rough bed of crushed ice only complicates the issue. Accordingly, systems and methods of the invention may include replicating the geometry of the chest cavity and/or the orientation of the lung therein during transport and storage of donor lungs. In certain embodiments, a lung or pair of lungs may be placed horizontally on a smooth surface with a raised central saddle portion to replicate the spine. Alternatively, a lung or pair of lungs may be suspended in an upright position similar to the orientation of the lung in a standing human body. In such instances, the lung or lungs may be suspended by the trachea or bronchus which may be secured to a support tube in fluid communication with, for example, an expandable accumulator as described above.
Systems and methods of the invention have application in both static cold storage devices and hypothermic machine perfusion devices. In certain embodiments, hypothermic machine perfusion devices are configured to oxygenate and perfuse a bodily tissue for extracorporeal preservation of the bodily tissue. In lung applications, the perfusate may be pumped through the lung's vasculature and kept separate from the closed airway-accumulator air system described above. The perfusion apparatuses can include a pneumatic system, a pumping chamber, and an organ chamber. The pneumatic system may be configured for the controlled delivery of fluid to and from the pumping chamber based on a predetermined control scheme. The predetermined control scheme can be, for example, a time-based control scheme or a pressure-based control scheme. The pumping chamber is configured to diffuse a gas into a perfusate and to generate a pulse wave for moving the perfusate through a bodily tissue. The organ chamber is configured to receive the bodily tissue and the perfusate. The organ chamber is configured to substantially automatically purge excess fluid from the organ chamber to the pumping chamber. The pumping chamber may be configured to substantially automatically purge excess fluid from the pumping chamber to an area external to the apparatus.
Devices, systems and methods are described herein that are configured for extracorporeal preservation and transportation of bodily tissue. Specifically, devices for monitoring and stabilizing pressure within inflated lungs are described. Systems and methods can compensate for pressure changes resulting from, for example, increases and decreases in altitude during air transport of the organ. By bleeding off and returning excess gases, volumetric expansion of the lung (i.e., over-inflation) may be prevented, avoiding damaging the organ which can result in decreased organ viability and decreased survival rates for transplant recipients. Additional aspects include contoured storage and transport chambers that can replicate the in-vivo anatomical orientation and geometry for a given organ. For example, a pair of donor lungs may be placed against a smooth, raised, central saddle designed to replicate the spine that the lungs would be resting against in vivo. Organs, such as lungs or hearts, may be suspended in an upright position to replicate the organ's orientation in a standing human and to prevent tissue damage caused by pressure from the organ's own weight resting on itself.
The organ adapter 107 is coupled to an expandable accumulator 105 and the lumen of the organ adapter 107 is in fluid communication with a sealed interior volume of the expandable accumulator 105. The expandable accumulator 105 may be coupled by a valve 109, to an inlet 113. The inlet 113 has a lumen that, when the valve 109 is open, is in fluid communication with the interior volume of the expandable accumulator 105, the lumen of the organ adapter 107, and the airways of the lung 103. When the valve 109 is closed, the interior volume of the expandable accumulator 105, the lumen of the organ adaptor 107, and the airways of the lung 103 form an air-tight, closed environment that is sealed from the outside environment including, for example, any preservation fluid present within the organ container 111. The organ container 111 may include one or more boxes or bags configured to contain both the organ and any preservation fluid (e.g., temperature regulated, oxygenated fluid) in a sterilized environment. In preferred embodiments, the organ is placed into one or more sterile bags or boxes. For example, a lung may be placed in three concentric sterile bags fitted with a through-the-bag-wall cannula leading into the trachea plug. The cannula may include a filter for each bag (e.g., a 0.2-micron sterile filter). Accordingly, both the exterior surface and interior, pressure-dampened lumen of the organ are surrounded by three sterile layers.
In various embodiments, the accumulator may have an interior volume (fully expanded) of about, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 3.5, 4, 4.5, or more liters. In preferred embodiments, the accumulator has a fully expanded interior volume of about 1 liter.
System 101 is configured to permit gas to move back and forth between the airways of the lung 103 through the lumen of the organ adapter 107, and into the interior volume of the expandable accumulator 105. When the valve 109 is open, the system 101 is configured to permit gas flow from the inlet 113, through the valve 109, into the lumen of the organ adaptor 107, and finally into the airways of the lung 103. The expansion resistance of the expandable accumulator 105 may be adjustable, fixed, or progressive.
The organ adapter 107 may be configured to substantially retain the bodily tissue (e.g., lung) with respect to the expandable accumulator 105. The organ adapter 107 may be configured to permit movement of a gas from the expandable accumulator 105, into the airways of the lung 103, and back. The organ adapter 107 can be configured to be coupled to a bodily tissue such as a lung 103. The organ adapter 107 can be coupled to the bodily tissue in any suitable manner For example, in some embodiments, the organ adapter 107 can configured to be sutured to the bodily tissue. In another example, the organ adapter 107 is coupleable to the bodily tissue via an intervening structure, such as silastic or other tubing. In some embodiments, at least a portion of the organ adapter 107, or the intervening structure, is configured to be inserted into the bodily tissue such as the lumen of a trachea, bronchus, or other air passage of a lung 103. For example, in some embodiments, the lumen of the organ adapter 107 (or a lumen of the intervening structure) is configured to be fluidically coupled to a lumen of the bodily tissue such as an air passage of the lung 103.
In various embodiments including the use of one or more sterile bags or other containers for the organ, the organ adapter may be contained in or integral to the inner most sterile bag and coupled to a through-the-bag-wall cannula that transverses each of the bags or other containers. The cannula, at the outer most bag or other container, may include an adapter to be removably coupled to the accumulator in the systems described herein. Accordingly, the bagged organ may be easily and quickly connected to the accumulator and inflated during loading and easily and quickly disconnected upon arrival at the transplantation site.
In some embodiments, the organ adapter (or simply referred as the adapter) can be configured to support the bodily tissue when the bodily tissue is coupled to the adapter. For example, in some embodiments, the adapter can include a retention mechanism (not shown) configured to be disposed about at least a portion of the bodily tissue and to help retain the bodily tissue with respect to the adapter. The retention mechanism can be, for example, a net, a cage, a sling, or the like. In some embodiments, the system can include a basket (not shown) or other support mechanism configured to support the bodily tissue when the bodily tissue is coupled to the adapter or otherwise received in the system. The organ adapter may be rigidly coupled to an interior wall (e.g. a lid) of an organ container such that the organ may be suspended via its connection point to the adapter.
The portion of the adapter that is inserted into a lumen of the organ may include a series of tapered steps such that a distal end of the adapter portion is narrower than a proximal end. In this manner, the adapter is configured to be inserted into a range of lumen sizes.
The lumen may be secured or sealed to the organ adapter via any means including elastic tension in the organ lumen itself or through the use of sutures, elastic band, or other securing mechanisms on the outside of the lumen applying pressure thereupon to form an air-tight seal between the lumen of the organ and the lumen of the adapter.
The expandable accumulator is configured to expand to accept relative increases in gas volume within the closed system in response to pressure differential changes between the closed system and the surrounding environment (e.g., during flight). The interior volume of the expandable accumulator should resist expansion with an opposing force that is less than that of the lung. Accordingly, decreases in internal pressure of the closed system due to decreases in the pressure of the surrounding environment (e.g. during flight) will be borne by the expandable accumulator such that the pressure within the system drops without volumetric expansion of the lung airways (which could cause tissue damage or rupture the airways).
The expandable accumulator is configured to be in constant communication with the internal (closed system) pressure and the external (surrounding environment) pressure, and to establish a nearly-constant differential between the two while having compliance higher than the lung's compliance. The pressure differential is such that the internal pressure is greater than the environment pressure. The pressure differential keeps the lungs inflated. The pressure differential would commonly be referred to as the gauge pressure. When the system is initially prepared, the external pressure may be 1 bar (absolute) and the internal pressure would be 1+x bar, absolute (where the x is a suitable value chosen for best storage performance). The gauge pressure of the closed system is therefore x bar, and the differential pressure across the lung is also x bar. At a later time, in transport, the external pressure may be 0.75 bar for instance due to airplane cabin pressure when in flight. The internal pressure would be 0.75+x bar, so the gauge pressure is again x bar, as is the pressure across the lung. In this manner the expandable accumulator maintains a nearly-constant pressure differential across the lung (from inside to outside).
In order to maintain the nearly-constant pressure differential the expandable accumulator will have a very high compliance, for example much higher than the lung compliance. In certain embodiments, the system may be configured to maintain about a 15 cm H2O gauge pressure inside the organ. The pressure may be fixed or may be tunable or adjustable using variable weight, spring tension, or other means depending on the accumulator mechanism. Pressure in the system may be set by filling the system to a desired fixed pressure or may be controlled using an adjustable accumulator which may be acted on by a computer based on inputs received from a pressure or other sensor as described below.
An inlet of the system may be used to add or remove a gas from the lumen of the organ (e.g., airways of a lung). For example, where donor lungs are at least partially inflated for storage and transport, a retrieved lung may be secured to an organ adapter as shown in
During inflation, as gas is admitted to the system, both the lungs and the expandable accumulator will inflate until reaching the desired gauge pressure (designated “x” above). As additional gas is thereafter admitted, the gas would preferentially fill the expandable accumulator given that component's higher compliance. When the expandable accumulator is entirely filled, the pressure would begin to rise above the “x” target, and the system would not have any remaining capacity. Therefore, when the system is filled the volume of gas may be adjusted such that a movable element of the expandable accumulator rests at a target position (for instance 25% of travel). Once the expandable accumulator is at that target position, the valve can be closed and the closed system is sealed and ready for transport.
Once the lung has been inflated to a desired pressure, the valve may be closed, sealing off the closed system. The lung coupled to the expandable accumulator by the organ adapter along with the closed valve and the inlet may be then be placed in an organ container for storage or transport and may be at least partially submerged in a fluid such as a preservation fluid as known in the art. Examples of preservation fluid and static and perfusion-based tissue containers compatible with systems and methods of the invention are described in U.S. application Ser. No. 14/460,489, incorporated herein by reference.
The fill of the accumulator can be adjusted at organ recovery according to the local ambient (e.g. barometric) pressure. A smaller accumulator would thereby be able to work identically whether filled in Denver CO, or Boston Mass., whatever the weather conditions. The accumulator may include a scale or other indicator in customary barometric pressure units. An exemplary pressure indicator 1115 is shown in
The expandable accumulator may be of any configuration that permits expansion of its interior volume with less resistance than that of the lung's airways. Examples of expandable accumulators are shown in
The expandable accumulator 105 depicted in
The rolling diaphragm contributes to a low-friction, low-hysteresis accumulator advantageous to tissue preservation as described herein, especially in lung preservation and transport apparatuses. The diaphragm may be constructed of any suitable material including latex, rubber, or silicon.
A diaphragm-type accumulator system as exemplified in
As noted, systems of the invention are compatible with and may include any static or perfusion-type preservation apparatus. An example of such a configuration is shown in
The membrane 20 is disposed within the pumping chamber 14 along an axis Al that is transverse to a horizontal axis A2. Said another way, the membrane 20 is inclined, for example, from a first side 22 to a second side 24 of the apparatus 10. As such, as described in more detail below, a rising fluid in the second portion 18 of the pumping chamber 14 will be directed by the inclined membrane 20 towards a port 38 disposed at the highest portion of the pumping chamber 14. The port 38 is configured to permit the fluid to flow from the pumping chamber 14 into the atmosphere external to the apparatus 10. In some embodiments, the port 38 is configured for unidirectional flow, and thus is configured to prevent a fluid from being introduced into the pumping chamber 14 via the port (e.g., from a source external to the apparatus 10). In some embodiments, the port 38 includes a luer lock.
The second portion 18 of the pumping chamber 14 is configured to receive a fluid. In some embodiments, for example, the second portion 18 of the pumping chamber 14 is configured to receive a liquid perfusate. The second portion 18 of the pumping chamber 14 is in fluid communication with an adapter 26. The adapter 26 is configured to permit movement of the fluid from the pumping chamber 14 to a bodily tissue T. For example, in some embodiments, the pumping chamber 14 defines an aperture (not shown) configured to be in fluidic communication with a lumen (not shown) of the adapter 26. The adapter 26 is configured to be coupled to the bodily tissue T. The adapter 26 can be coupled to the bodily tissue T in any suitable manner For example, in some embodiments, the adapter 26 is configured to be sutured to the bodily tissue T. In another example, the adapter 26 is coupleable to the bodily tissue T via an intervening structure, such as silastic or other tubing. In some embodiments, at least a portion of the adapter 26, or the intervening structure, is configured to be inserted into the bodily tissue T. For example, in some embodiments, the lumen of the adapter 26 (or a lumen of the intervening structure) is configured to be fluidically coupled to a vessel of the bodily tissue T.
Where the tissue T is, for example a lung, the airways of the tissue T may be coupled to an expandable accumulator 705 and associated systems as described herein via an organ adapter 707 (e.g., via the trachea or bronchus).
In some embodiments, the adapter 26 is configured to support the bodily tissue T when the bodily tissue T is coupled to the adapter. For example, in some embodiments, the adapter 26 includes a retention mechanism (not shown) configured to be disposed about at least a portion of the bodily tissue T and to help retain the bodily tissue T with respect to the adapter. The retention mechanism can be, for example, a net, a cage, a sling, or the like. In some embodiments, the apparatus 10 includes a basket (not shown) or other support mechanism configured to support the bodily tissue T when the bodily tissue T is coupled to the adapter 26 or otherwise received in the apparatus 10.
An organ chamber 30 is configured to receive the bodily tissue T and a fluid. In some embodiments, the apparatus 10 includes a port 34 that is extended through the apparatus 10 (e.g., through the pumping chamber 14) to the organ chamber 30. The port 34 is configured to permit fluid (e.g., perfusate) to be introduced to the organ chamber 30. In this manner, fluid can be introduced into the organ chamber 30 as desired by an operator of the apparatus. For example, in some embodiments, a desired amount of perfusate is introduced into the organ chamber 30 via the port 34, such as before disposing the bodily tissue T in the organ chamber 30 and/or while the bodily tissue T is received in the organ chamber. In some embodiments, the port 34 is a unidirectional port, and thus is configured to prevent the flow of fluid from the organ chamber 30 to an area external to the organ chamber through the port. In some embodiments, the port 34 includes a luer lock. The organ chamber 30 may be of any suitable volume necessary for receiving the bodily tissue T and a requisite amount of fluid for maintaining viability of the bodily tissue T. In one embodiment, for example, the volume of the organ chamber 30 is approximately 2 liters.
The organ chamber 30 is formed by a canister 32 and a bottom portion 19 of the pumping chamber 14. In a similar manner as described above with respect to the membrane 20, an upper portion of the organ chamber (defined by the bottom portion 19 of the pumping chamber 14) can be inclined from the first side 22 towards the second side 24 of the apparatus. In this manner, as described in more detail below, a rising fluid in the organ chamber 30 will be directed by the inclined upper portion of the organ chamber towards a valve 36 disposed at a highest portion of the organ chamber. The valve 36 is configured to permit a fluid to flow from the organ chamber 30 to the pumping chamber 14. The valve 36 is configured to prevent flow of a fluid from the pumping chamber 14 to the organ chamber. The valve 36 can be any suitable valve for permitting unidirectional flow of the fluid, including, for example, a ball check valve.
The canister 32 can be constructed of any suitable material. In some embodiments, the canister 32 is constructed of a material that permits an operator of the apparatus 10 to view at least one of the bodily tissue T or the perfusate received in the organ chamber 30. For example, in some embodiments, the canister 32 is substantially transparent. In another example, in some embodiments, the canister 32 is substantially translucent. The organ chamber 30 can be of any suitable shape and/or size. For example, in some embodiments, the organ chamber 30 can have a perimeter that is substantially oblong, oval, round, square, rectangular, cylindrical, or another suitable shape.
In use, the bodily tissue T is coupled to the adapter 26. The pumping chamber 14 is coupled to the canister 32 such that the bodily tissue T is received in the organ chamber 30. In some embodiments, the pumping chamber 14 and the canister 32 are coupled such that the organ chamber 30 is hermetically sealed. A desired amount of perfusate is introduced into the organ chamber 30 via the port 34. The organ chamber 30 can be filled with the perfusate such that the perfusate volume rises to the highest portion of the organ chamber. The organ chamber 30 can be filled with an additional amount of perfusate such that the perfusate flows from the organ chamber 30 through the valve 36 into the second portion 18 of the pumping chamber 14. The organ chamber 30 can continue to be filled with additional perfusate until all atmospheric gas that initially filled the second portion 18 of the pumping chamber 14 rises along the inclined membrane 20 and escapes through the port 38. Because the gas will be expelled from the pumping chamber 14 via the port 38 before any excess perfusate is expelled (due to gas being lighter, and thus more easily expelled, than liquid), an operator of the apparatus 10 can determine that substantially all excess gas has been expelled from the pumping chamber when excess perfusate is released via the port. As such, the apparatus 10 can be characterized as self-purging. When perfusate begins to flow out of the port 38, the apparatus 10 is in a “purged” state (i.e., all atmospheric gas initially within the organ chamber 30 and the second portion 18 of the pumping chamber 14 has been replaced by perfusate). When the purged state is reached, the operator can close both ports 34 and 38, preparing the apparatus 10 for operation.
Oxygen (or another suitable fluid, e.g., gas) is introduced into the first portion 16 of the pumping chamber 14 via the valve 12. A positive pressure generated by the introduction of oxygen into the pumping chamber 14 causes the oxygen to be diffused through the semi-permeable membrane 20 into the second portion 18 of the pumping chamber. Because oxygen is a gas, the oxygen expands to substantially fill the first portion 16 of the pumping chamber 14. As such, substantially the entire surface area of the membrane 20 between the first portion 16 and the second portion 18 of the pumping chamber 14 is used to diffuse the oxygen. The oxygen is diffused through the membrane 20 into the perfusate received in the second portion 18 of the pumping chamber 14, thereby oxygenating the perfusate.
In the presence of the positive pressure, the oxygenated perfusate is moved from the second portion 18 of the pumping chamber 14 into the bodily tissue T via the adapter 26. For example, the positive pressure can cause the perfusate to move from the pumping chamber 14 through the lumen of the adapter 26 into the vessel of the bodily tissue T. The positive pressure is also configured to help move the perfusate through the bodily tissue T such that the bodily tissue T is perfused with oxygenated perfusate.
After the perfusate is perfused through the bodily tissue T, the perfusate is received in the organ chamber 30. In this manner, the perfusate that has been perfused through the bodily tissue T is combined with perfusate previously disposed in the organ chamber 30. In some embodiments, the volume of perfusate received from the bodily tissue T following perfusion combined with the volume of perfusate previously disposed in the organ chamber 30 exceeds a volume (e.g., a maximum fluid capacity) of the organ chamber 30. A portion of the organ chamber 30 is flexible and expands to accept this excess volume. The valve 12 can then allow oxygen to vent from the first portion 16 of the pumping chamber 14, thus, reducing the pressure in the pumping chamber 14. As the pressure in the pumping chamber 14 drops, the flexible portion of the organ chamber 30 relaxes, and the excess perfusate is moved through the valve 36 into the pumping chamber 14. The cycle of oxygenating perfusate and perfusing the bodily tissue T with the oxygenated perfusate can be repeated as desired.
The interior of organ containers of the invention may contain a fixed or removable shelf or tray configured to support cooling materials (e.g., frozen gel packs). Such a tray allows the organ to be loaded into the container before the tray is in place and, once the tray is inserted, the tray supports the cooling materials keeping them proximate to the organ for cooling purposes but prevents the materials from contacting the organ which can cause damage thereto. The tray may further serve to locate the organ within the colder bottom portion of the container.
Systems of the invention may include a variety of sensors configured to sense and report, for example, temperature of the tissue, temperature of a preservation fluid or perfusate, pressure within the closed air system, pressure within the fluid, or ambient pressure. Displays for the sensors may be disposed on the outer surfaces of the organ transport or may be wirelessly linked to the internal sensors.
In some embodiments, a temperature sensor may include a probe positioned in the transport cavity and attached by a flexible cable to a temperature datalogger. The probe may not be wetted (i.e., the probe would remain outside of any sterile bags or containers) and may be suspended in air by a bracket or support in order to avoid direct contact with any cooling materials. The probe would thereby record and/or report the cavity temperature rather than the lung tissue temperature.
In certain embodiments, the sensor may comprise a mechanical flag that indicates the furthest expansion of the expandable accumulator and can therefore indicate if the accumulator reached maximum expansion presenting the possibility that additional pressure was absorbed by the lung tissue through over-inflation.
As one skilled in the art would recognize as necessary or best-suited for the systems and methods of the invention, systems and methods of the invention may include computers that may include one or more of processor (e.g., a central processing unit (CPU), a graphics processing unit (GPU), etc.), computer-readable storage device (e.g., main memory, static memory, etc.), or combinations thereof which communicate with each other via a bus. Computers may include mobile devices (e.g., cell phones), personal computers, and server computers. In various embodiments, computers may be configured to communicate with one another via a network in order to display image series or allow remote storage, viewing, or selection of images of a given series.
A processor may include any suitable processor known in the art, such as the processor sold under the trademark XEON E7 by Intel (Santa Clara, Calif.) or the processor sold under the trademark OPTERON 6200 by AMD (Sunnyvale, Calif.).
Memory preferably includes at least one tangible, non-transitory medium capable of storing: one or more sets of instructions executable to cause the system to perform functions described herein (e.g., software embodying any methodology or function found herein); data (e.g., portions of the tangible medium newly re-arranged to represent real world physical objects of interest accessible as, for example, a picture of an object like a motorcycle); or both. While the computer-readable storage device can in an exemplary embodiment be a single medium, the term “computer-readable storage device” should be taken to include a single medium or multiple media (e.g., a centralized or distributed database, and/or associated caches and servers) that store the instructions or data. The term “computer-readable storage device” shall accordingly be taken to include, without limit, solid-state memories (e.g., subscriber identity module (SIM) card, secure digital card (SD card), micro SD card, or solid-state drive (SSD)), optical and magnetic media, hard drives, disk drives, and any other tangible storage media.
Input/output devices according to the invention may include one or more of a video display unit (e.g., a liquid crystal display (LCD) or a cathode ray tube (CRT) monitor), an alphanumeric input device (e.g., a keyboard), any temperature, pressure, or other sensor described herein, a cursor control device (e.g., a mouse or trackpad), a disk drive unit, a signal generation device (e.g., a speaker), a touchscreen, a button, an accelerometer, a microphone, a cellular radio frequency antenna, a network interface device, which can be, for example, a network interface card (NIC), Wi-Fi card, or cellular modem, or any combination thereof.
One of skill in the art will recognize that any suitable development environment or programming language may be employed to allow the operability described herein for various systems and methods of the invention. For example, systems and methods herein can be implemented using Perl, Python, C++, C#, Java, JavaScript, Visual Basic, Ruby on Rails, Groovy and Grails, or any other suitable tool. For a computer, it may be preferred to use native xCode or Android Java.
Lung volume and pressure conditions were modeled during transport without an accumulator, with a spring-based accumulator, and with a weight based accumulator (as described above). Since PV=nRT (ideal gas law) the trapped volume inside the lung will obey pV/T=constant or pf Vf/Tf=po Vo/To where “o” refers to starting and “f” to final conditions.
P is the atmospheric pressure, absolute. p is the internal pressure, absolute, biased somewhat above P. V is the contained volume (lung, tubing, accumulator) T is the temperature in Kelvin.
For pressure the model defines and uses cmH2O and atm (the SI unit standard). Pressure measurements are absolute unless otherwise stated.
Ambient Condition Ranges:
Ambient Pressure (P) can range between the following (note that weather measurements are usually in inHg)
1atm=29.921in_HgPatmmin=25.69in_Hg=0.899atmPatmmax:=32.06in_Hg=1.071atm
Altitude at recovery should be accounted for. For example, the typical pressure in a city such as Denver, Colo. may be calculated as:
The range of Po is from ˜0.8 to ˜1.08 atm. Lung temperature (T) can range between the following (assumes that recovery occurs in cold operating rooms and transport is under not as cold conditions):
To_min:=2° C.=275.15K and To_max:=65° F.=291.483K
Travel Conditions:
To model transit conditions, it is assumed that T stays approximately constant. Allowing Tf to rise to 8° C. is conservative. Extremes of pressure will be seen in airplane cabins and is approximated as follows for various aircraft (Cabin Pressure is typically measured in equivalent altitude):
Regulatory Maximum=2400 m (patmosphere(2400 m)=0.752 atm)
Boeing 767=2100 m (patmosphere(2100 m)=0.780 atm) (typical of older airliners)
Airbus A380=1868 m (patmosphere(1868 m)=0.801 atm)
Boeing 747-400=1572 m (patmosphere(1572 m)=0.830 atm)
So flight pressures can range from 0.752 up to 0.830 atm.
Range Values for Exploring Solution Space:
i:=0 . . . 50 (where i is the ambient pressure index); j:=0 . . . 2 (where j is the initial conditions index for solutions of multiple cases simultaneously); Pmin:=0.75 atm and Pmax:=1.10 atm
Lung Parameters:
The lung values used herein are taken from literature. The volumes at 40 cmH2O and above are extrapolated. The resulting interpolated lung pressure-volume model is large: volume is 4.74 liters at 15 cmH2O. The pressure-volume model was scaled to establish a resting volume of 3.5 L at 15 cmH2O.″
Vrest:=3.5 L; Prest:=15 cmH2O
LungV (p, P):=interp[1spline(Lungp, Lungv), Lungp, Lungv, (p-P)]
LungV(Prest, 0 cmH2O)=4.474 L
Vlungmax=5 L (this simulates a volume constraint from a perfectly rigid lung) The scaled, max-limited Lung Volume formula is then:
(where =internal and P =external pressure, absolute)
A graph of the lung curve can be modeled using the following equation:
A graph of the target volume, pressure and target compliance can be created as follows:
The curve of an ex-vivo lung model, volume vs. pressure is shown in
Accumulator parameters for the model were varied based on the accumulator used as follows:
1) No Accumulator:
AccumPresent=0(When this is zero, there's no accumulator in the system).
Vacm1trmin=50 mL Vacm1trmax=1500.0 mL (These values represent the designed volume range)
(this is set by the recovery team, e.g. system is filled with air until accumulator is at the stipulated volume, which may vary based on ambient pressure at time/place of recovery)
(Higher numbers here represent a weight-loaded design; lower numbers represent a spring-loaded design)
ΔPacm1tr=15·cmH2O
(This is the nominal accumulator pressure, at Vacm1trrecovery1, e.g., when the piston is at the target volume for the nominal pressure case. It is set by the weight or spring)
Hspringmin:=1 in (This is the spring height at max compression)
(This is the free height of the spring and not meaningful for weight-biased designs)
2) Spring-Based Accumulator:
Parameters are same as for no accumulator above aside from the following:
3) Weight-Based Accumulator:
Parameters are same as for no accumulator above aside from the following
Initial Conditions:
where Po is the external environmental pressure.
The accumulator's behavior was used to determine Po and Vo, e.g., the initial internal pressure volume at the above Po and To given all other parameters. The accumulator is filled to the target volume, which sets the internal pressure.
The lung volume was determined by the initial and external pressures as:
Vlunginitial=Vlung(po, Po)=3.5L
The Contained Volume Vo is the sum of accumulator and lung volumes. This is the initial volume of air inside the system. This mass of air will remain unchanged, so the ideal gas law governs its subsequent behavior (relationship of pressure to volume). Vo can be defined as follows for the various accumulator types:
No Accumulator:
Spring-Based Accumulator:
Weight-Based Accumulator:
The equation for final volume Vf is based on the ideal gas law for contained volume,
solved for Vf:
The adapted equation was used in the solve function below:
Pguess:=1.2·po
given:
with the following constraint added:
Pguess>Ptravel
providing a solution of:
ptravel(po, Vo, To, Tf, Ptravel):=Find)pguess)
The inputs to this function are the initial conditions together with travel pressure and temperature. The output of this function is the internal pressure.
The solution for a defined range of conditions can then be found:
ptravel
Vlungtravel
Vacmltrtravel
ΔPlung
Initial conditions:
Lung parameters:
In-transit temperature:
Given the above values,
As shown in
Initial Conditions:
Lung Parameters:
In-transit temperature:
Regulatory Minimum=0.75 atm
Older Airplanes=0.78 atm
Newer Airplanes=0.80-0.83 atm
Given the above values,
Initial Conditions:
Lung Parameters:
In-transit temperature:
Tf=8° C.
Airplane cabin pressures:
Given the above values,
References and citations to other documents, such as patents, patent applications, patent publications, journals, books, papers, web contents, have been made throughout this disclosure. All such documents are hereby incorporated herein by reference in their entirety for all purposes.
Various modifications of the invention and many further embodiments thereof, in addition to those shown and described herein, will become apparent to those skilled in the art from the full contents of this document, including references to the scientific and patent literature cited herein. The subject matter herein contains important information, exemplification and guidance that can be adapted to the practice of this invention in its various embodiments and equivalents thereof.
This application is a divisional application of U.S. non-provisional application Ser. No. 16/002795, filed Jun. 7, 2018, which application claims the benefit of and priority to U.S. provisional patent application Ser. Nos. 62/516,581, filed Jun. 7, 2017, 62/584,330, filed Nov. 10, 2017, and 62/650,610, filed Mar. 30, 2018, all of the contents of which are incorporated by reference herein in their entirety.
Number | Name | Date | Kind |
---|---|---|---|
3398743 | Shalit | Aug 1968 | A |
3607646 | de Roissart | Sep 1971 | A |
3935065 | Doerig | Jan 1976 | A |
4336248 | Bonhard et al. | Jun 1982 | A |
4575498 | Holmes et al. | Mar 1986 | A |
4643713 | Viitala | Feb 1987 | A |
4952409 | Bando et al. | Aug 1990 | A |
4976708 | Oshiyama | Dec 1990 | A |
5066578 | Wikman-Coffelt | Nov 1991 | A |
5141847 | Sugimachi et al. | Aug 1992 | A |
5149321 | Klatz et al. | Sep 1992 | A |
5186431 | Tamari | Feb 1993 | A |
5234405 | Klatz et al. | Aug 1993 | A |
RE34387 | Holmes et al. | Sep 1993 | E |
5252537 | De Winter-Scailteur | Oct 1993 | A |
5306711 | Andrews | Apr 1994 | A |
5320846 | Bistrian et al. | Jun 1994 | A |
5326706 | Yland et al. | Jul 1994 | A |
5356771 | O'Dell | Oct 1994 | A |
5362622 | O'Dell et al. | Nov 1994 | A |
5385821 | O'Dell et al. | Jan 1995 | A |
5395314 | Klatz et al. | Mar 1995 | A |
5434045 | Jost | Jul 1995 | A |
5584804 | Klatz et al. | Dec 1996 | A |
5586438 | Fahy | Dec 1996 | A |
5599659 | Brasile et al. | Feb 1997 | A |
5601972 | Meryman | Feb 1997 | A |
5629145 | Meryman | May 1997 | A |
5643712 | Brasile | Jul 1997 | A |
5656154 | Meryman | Aug 1997 | A |
5696152 | Southard | Dec 1997 | A |
5699793 | Brasile | Dec 1997 | A |
5702881 | Brasile et al. | Dec 1997 | A |
5707971 | Fahy | Jan 1998 | A |
5709654 | Klatz et al. | Jan 1998 | A |
5712084 | Osgood | Jan 1998 | A |
5716378 | Minten | Feb 1998 | A |
5752929 | Klatz et al. | May 1998 | A |
5827222 | Klatz et al. | Oct 1998 | A |
5843024 | Brasile | Dec 1998 | A |
5916800 | Elizondo et al. | Jun 1999 | A |
5922598 | Mintchev | Jul 1999 | A |
5963335 | Boutelle | Oct 1999 | A |
5965433 | Gardetto et al. | Oct 1999 | A |
6014864 | Owen | Jan 2000 | A |
6020575 | Nagle et al. | Feb 2000 | A |
6024698 | Brasile | Feb 2000 | A |
6046046 | Hassanein | Apr 2000 | A |
6060232 | Von Baeyer et al. | May 2000 | A |
6100082 | Hassanein | Aug 2000 | A |
6174719 | Elizondo et al. | Jan 2001 | B1 |
6194137 | Khirabadi et al. | Feb 2001 | B1 |
6209343 | Owen | Apr 2001 | B1 |
6241945 | Owen | Jun 2001 | B1 |
6280925 | Brockbank | Aug 2001 | B1 |
6303388 | Fahy | Oct 2001 | B1 |
D453828 | Brassil et al. | Feb 2002 | S |
6375613 | Brasile | Apr 2002 | B1 |
6406839 | Segall et al. | Jun 2002 | B1 |
6413713 | Serebrennikov | Jul 2002 | B1 |
6475716 | Seki | Nov 2002 | B1 |
6485450 | Owen | Nov 2002 | B1 |
6492103 | Taylor | Dec 2002 | B1 |
D468436 | Brassil et al. | Jan 2003 | S |
D470594 | Brassil et al. | Feb 2003 | S |
6569615 | Thatte et al. | May 2003 | B1 |
6582953 | Brasile | Jun 2003 | B2 |
6596531 | Campbell et al. | Jul 2003 | B2 |
6642019 | Anderson et al. | Nov 2003 | B1 |
6642045 | Brasile | Nov 2003 | B1 |
6656380 | Wood et al. | Dec 2003 | B2 |
6673008 | Thompson et al. | Jan 2004 | B1 |
6673594 | Owen et al. | Jan 2004 | B1 |
6677150 | Alford et al. | Jan 2004 | B2 |
6699231 | Sterman et al. | Mar 2004 | B1 |
6736836 | Montgomery | May 2004 | B2 |
6740484 | Khirabadi et al. | May 2004 | B1 |
6773877 | Fahy | Aug 2004 | B2 |
6794124 | Steen | Sep 2004 | B2 |
6794182 | Wolf, Jr. | Sep 2004 | B2 |
6905871 | Doorschodt et al. | Jun 2005 | B1 |
6924267 | Daemen et al. | Aug 2005 | B2 |
6953655 | Hassanein et al. | Oct 2005 | B1 |
6977140 | Owen et al. | Dec 2005 | B1 |
6994954 | Taylor | Feb 2006 | B2 |
7005253 | Polyak et al. | Feb 2006 | B2 |
7008535 | Spears et al. | Mar 2006 | B1 |
7029839 | Toledo-Pereyra et al. | Apr 2006 | B2 |
D531319 | Schein et al. | Oct 2006 | S |
D531320 | Garland et al. | Oct 2006 | S |
7157222 | Khirabadi et al. | Jan 2007 | B2 |
7176015 | Alford et al. | Feb 2007 | B2 |
7270946 | Brockbank et al. | Sep 2007 | B2 |
7294278 | Spears et al. | Nov 2007 | B2 |
7316922 | Streeter | Jan 2008 | B2 |
7326564 | Lundell et al. | Feb 2008 | B2 |
7361365 | Birkett et al. | Apr 2008 | B2 |
7410474 | Friend et al. | Aug 2008 | B1 |
7504201 | Taylor et al. | Mar 2009 | B2 |
7572622 | Hassanein et al. | Aug 2009 | B2 |
7651835 | Hassanein et al. | Jan 2010 | B2 |
7678563 | Wright et al. | Mar 2010 | B2 |
7691622 | Garland et al. | Apr 2010 | B2 |
7749693 | Brassil et al. | Jul 2010 | B2 |
7811808 | van der Plaats et al. | Oct 2010 | B2 |
7824848 | Owen et al. | Nov 2010 | B2 |
7897327 | Millis et al. | Mar 2011 | B2 |
8097449 | Garland et al. | Jan 2012 | B2 |
8268547 | Owen et al. | Sep 2012 | B2 |
8268612 | Owen et al. | Sep 2012 | B2 |
8304181 | Hassanein et al. | Nov 2012 | B2 |
8420380 | Fishman et al. | Apr 2013 | B2 |
8465970 | Hassanein et al. | Jun 2013 | B2 |
8785116 | Anderson et al. | Jul 2014 | B2 |
8828710 | Anderson et al. | Sep 2014 | B2 |
8835158 | Judson | Sep 2014 | B2 |
9426979 | Anderson et al. | Aug 2016 | B2 |
11166542 | Sze | Nov 2021 | B2 |
20010025191 | Montgomery | Sep 2001 | A1 |
20020042131 | Brockbank et al. | Apr 2002 | A1 |
20020051779 | Gage et al. | May 2002 | A1 |
20020064768 | Polyak et al. | May 2002 | A1 |
20020068360 | Brockbank et al. | Jun 2002 | A1 |
20020115634 | Polyak et al. | Aug 2002 | A1 |
20020177117 | Wolf | Nov 2002 | A1 |
20030022148 | Seki | Jan 2003 | A1 |
20030053998 | Daemen et al. | Mar 2003 | A1 |
20030118980 | Taylor | Jun 2003 | A1 |
20030125804 | Kruse et al. | Jul 2003 | A1 |
20030180704 | Brockbank et al. | Sep 2003 | A1 |
20040014199 | Streeter | Jan 2004 | A1 |
20040038192 | Brasile | Feb 2004 | A1 |
20040038193 | Brasile | Feb 2004 | A1 |
20040058432 | Owen et al. | Mar 2004 | A1 |
20040067480 | Brockbank et al. | Apr 2004 | A1 |
20040111104 | Schein et al. | Jun 2004 | A1 |
20040170950 | Prien | Sep 2004 | A1 |
20040171138 | Hassanein et al. | Sep 2004 | A1 |
20040221719 | Wright et al. | Nov 2004 | A1 |
20040224298 | Brassil et al. | Nov 2004 | A1 |
20040224299 | Garland et al. | Nov 2004 | A1 |
20040241634 | Millis et al. | Dec 2004 | A1 |
20040248281 | Wright et al. | Dec 2004 | A1 |
20050100876 | Khirabadi et al. | May 2005 | A1 |
20050147958 | Hassanein et al. | Jul 2005 | A1 |
20050153271 | Wenrich | Jul 2005 | A1 |
20050221269 | Taylor et al. | Oct 2005 | A1 |
20050233299 | Sawa et al. | Oct 2005 | A1 |
20050255442 | Brassil et al. | Nov 2005 | A1 |
20050277106 | Daemen et al. | Dec 2005 | A1 |
20060019388 | Hutmacher et al. | Jan 2006 | A1 |
20060063142 | Owen et al. | Mar 2006 | A1 |
20060121439 | Baker | Jun 2006 | A1 |
20060121512 | Parenteau | Jun 2006 | A1 |
20060121605 | Parenteau | Jun 2006 | A1 |
20060141077 | Pettersson | Jun 2006 | A1 |
20060148062 | Hassanein et al. | Jul 2006 | A1 |
20060154357 | Hassanein et al. | Jul 2006 | A1 |
20060154358 | Hassanein et al. | Jul 2006 | A1 |
20060154359 | Hassanein et al. | Jul 2006 | A1 |
20060160204 | Hassanein et al. | Jul 2006 | A1 |
20060168985 | Gano | Aug 2006 | A1 |
20060292544 | Hassanein et al. | Dec 2006 | A1 |
20070009881 | Arzt et al. | Jan 2007 | A1 |
20070015131 | Arzt et al. | Jan 2007 | A1 |
20070166292 | Brasile | Jul 2007 | A1 |
20070184545 | Plaats et al. | Aug 2007 | A1 |
20070190636 | Hassanein et al. | Aug 2007 | A1 |
20070243518 | Serna et al. | Oct 2007 | A1 |
20070275364 | Hassanein et al. | Nov 2007 | A1 |
20080017194 | Hassanein et al. | Jan 2008 | A1 |
20080070229 | Streeter | Mar 2008 | A1 |
20080070302 | Brockbank et al. | Mar 2008 | A1 |
20080096184 | Brasile | Apr 2008 | A1 |
20080145919 | Franklin et al. | Jun 2008 | A1 |
20080187901 | Doorschodt et al. | Aug 2008 | A1 |
20080234768 | Hassanein et al. | Sep 2008 | A1 |
20080286747 | Curtis et al. | Nov 2008 | A1 |
20080288399 | Curtis et al. | Nov 2008 | A1 |
20080311552 | Min | Dec 2008 | A1 |
20090197240 | Fishman et al. | Aug 2009 | A1 |
20090197241 | Fishman et al. | Aug 2009 | A1 |
20090197292 | Fishman et al. | Aug 2009 | A1 |
20090197324 | Fishman et al. | Aug 2009 | A1 |
20090197325 | Fishman et al. | Aug 2009 | A1 |
20090199904 | Babbitt et al. | Aug 2009 | A1 |
20090226878 | Taylor et al. | Sep 2009 | A1 |
20090240277 | Connors et al. | Sep 2009 | A1 |
20090291486 | Wenrich | Nov 2009 | A1 |
20100015592 | Doorschodt | Jan 2010 | A1 |
20100028850 | Brassil | Feb 2010 | A1 |
20100056966 | Toth | Mar 2010 | A1 |
20100086907 | Bunegin et al. | Apr 2010 | A1 |
20100112542 | Wright et al. | May 2010 | A1 |
20100151559 | Garland et al. | Jun 2010 | A1 |
20100171802 | Lee et al. | Jul 2010 | A1 |
20100209902 | Zal et al. | Aug 2010 | A1 |
20100216110 | Brockbank | Aug 2010 | A1 |
20100221696 | Owen et al. | Sep 2010 | A1 |
20100233670 | Gavish | Sep 2010 | A1 |
20100234928 | Rakhorst et al. | Sep 2010 | A1 |
20110033916 | Hutzenlaub et al. | Feb 2011 | A1 |
20110039253 | Owen et al. | Feb 2011 | A1 |
20110053256 | Owen et al. | Mar 2011 | A1 |
20110059429 | Owen et al. | Mar 2011 | A1 |
20110129810 | Owen et al. | Jun 2011 | A1 |
20110129908 | Owen et al. | Jun 2011 | A1 |
20110136096 | Hassanein et al. | Jun 2011 | A1 |
20110177487 | Simsir et al. | Jul 2011 | A1 |
20110183310 | Kravitz et al. | Jul 2011 | A1 |
20110212431 | Bunegin et al. | Sep 2011 | A1 |
20110217689 | Bunegin et al. | Sep 2011 | A1 |
20120116152 | Faulkner et al. | May 2012 | A1 |
20120148542 | Kravitz | Jun 2012 | A1 |
20120309078 | Anderson et al. | Dec 2012 | A1 |
20140087357 | Kohl et al. | Mar 2014 | A1 |
20140140815 | Shener-Irmakoglu et al. | May 2014 | A1 |
20140314881 | Reynolds et al. | Oct 2014 | A1 |
20140349273 | Anderson et al. | Nov 2014 | A1 |
20140356850 | Anderson et al. | Dec 2014 | A1 |
20140356933 | Anderson et al. | Dec 2014 | A1 |
20150017627 | Anderson et al. | Jan 2015 | A1 |
20160074234 | Abichandani et al. | Mar 2016 | A1 |
20180352807 | Judson et al. | Dec 2018 | A1 |
20190038388 | Schmitt et al. | Feb 2019 | A1 |
20190320649 | Bunegin | Oct 2019 | A1 |
20210400952 | Judson | Dec 2021 | A1 |
Number | Date | Country |
---|---|---|
2722615 | Oct 2009 | CA |
551741 | Jul 1974 | CH |
101322861 | Dec 2008 | CN |
105660603 | Jun 2016 | CN |
205337358 | Jun 2016 | CN |
19922310 | Nov 2000 | DE |
102005048625 | Apr 2007 | DE |
0376763 | Jul 1990 | EP |
2278874 | Feb 2011 | EP |
2480069 | Aug 2012 | EP |
8-169801 | Jul 1996 | JP |
2008120713 | May 2008 | JP |
9409274 | Apr 1994 | WO |
9512973 | May 1995 | WO |
9743899 | Nov 1997 | WO |
9915011 | Apr 1999 | WO |
0018225 | Apr 2000 | WO |
2000018226 | Apr 2000 | WO |
0060935 | Oct 2000 | WO |
0103505 | Jan 2001 | WO |
0137719 | May 2001 | WO |
0154495 | Aug 2001 | WO |
0178504 | Oct 2001 | WO |
0178505 | Oct 2001 | WO |
0195717 | Dec 2001 | WO |
0217714 | Mar 2002 | WO |
0226034 | Apr 2002 | WO |
0232225 | Apr 2002 | WO |
02089571 | Nov 2002 | WO |
04017838 | Mar 2004 | WO |
2004026031 | Apr 2004 | WO |
04052101 | Jun 2004 | WO |
04089085 | Oct 2004 | WO |
04089090 | Oct 2004 | WO |
04105484 | Dec 2004 | WO |
04110146 | Dec 2004 | WO |
05022994 | Mar 2005 | WO |
05074681 | Aug 2005 | WO |
05099588 | Oct 2005 | WO |
06033674 | Mar 2006 | WO |
06042138 | Apr 2006 | WO |
06052133 | May 2006 | WO |
06060709 | Jun 2006 | WO |
2007111495 | Oct 2007 | WO |
2007124044 | Nov 2007 | WO |
2008108996 | Sep 2008 | WO |
2008144021 | Nov 2008 | WO |
2008150587 | Dec 2008 | WO |
2009020412 | Feb 2009 | WO |
2009041806 | Apr 2009 | WO |
2009099939 | Aug 2009 | WO |
2009132018 | Oct 2009 | WO |
2010084424 | Jul 2010 | WO |
2010096821 | Aug 2010 | WO |
2011038251 | Mar 2011 | WO |
2012125782 | Sep 2012 | WO |
2015021513 | Feb 2015 | WO |
2015126853 | Aug 2015 | WO |
2018015548 | Jan 2018 | WO |
2018112072 | Jun 2018 | WO |
2018184100 | Oct 2018 | WO |
Entry |
---|
Machuca, T. et al. Advances in Lung Preservation. Surgical Clinics of North America 93(6)1373-1394, Dec. 2013. (Year: 2013). |
Ex Parte Quayle Action issued in U.S. Appl. No. 16/542,050, date of mailing: Aug. 20, 2021, 8 pages. |
Galasso, 2019, Inactivating hepatitis C virus in donor lungs using light therapies during normothermic ex vivo lung perfusion, Nature Communications, vol. 10, Article 481, 12 pages. |
Non-Final Office Action issued in U.S. Appl. No. 16/857,689, dated May 24, 2022, 14 pages. |
T'Hart, 2006, New Solutions in Organ Preservation, Transplantation Reviews 2006, 16:131-141. |
Bunegin, et al., Interstitial pO2 and High Energy Phosphates in the Canine Heart during Hyopthermic Preservation in a New, Portable, Pulsatile Perfusion Device, from the Department of Anesthesiology University of Texas Health Science Center at San Antonio, Texas; and Center for Cardiovascular Surgery of the Republic of Lithuania, Vilnius, Lithuania, vol. 3, No. 3, Oct. 1998, pp. 1-6. |
Bunegin, et al., The Application of Fluidics Based Technology for Perfusion Preservation of Adult, Human Sized, Canine Hearts, from the Department of Anesthesiology, Health Science Center at San Antonio, University of Texas, vol. 8, No. 1/2 (2003), pp. 73-78. |
Bunegin, et al., The Application of Fluidics Technology for Organ Preservation, Biomedical Instrumentation & Technology, Mar./Apr. 2004, pp. 155-164. |
Calhoon, et al., Twelve-Hour Canine Heart Preservation With a Simple, Portable Hypothermic Organ Perfusion Device, Ann Thorac Surg 1996:62:91-3. |
De Perrot, 2004, Lung preservation, Seminars in Thoracic and Cardiovascular Surgery, Saunders, Philadelphia, PA, US, 16(4):300-308. |
Extended European Search Report issued in European Patent Application No. 13828327.0, dated Feb. 9, 2016 (7 pages). |
Extended European Search Report issued in European Patent Application No. 18812781.5, dated Feb. 11, 2021, 8 pages. |
Final Office Action issued in U.S. Appl. No. 16/542,050, dated Jan. 13, 2021, 17 pages. |
International Preliminary Report on Patentability issued in International Application No. PCT/US2009/041274, dated Jun. 24, 2009 (5 pages). |
International Search Report and Written Opinion issued in International Application No. PCT/US2009/041274, dated Jun. 24, 2009 (6 pages). |
International Search Report and Written Opinion issued in International Application No. PCT/US2010/050230, dated Feb. 14, 2011 (12 pages). |
International Search Report and Written Opinion issued in International Application No. PCT/US2013/054353, dated Dec. 16, 2013 (8 pages). |
International Search Report and Written Opinion issued in International Application No. PCT/US2013/054365, dated Dec. 9, 2013 (10 pages). |
International Search Report and Written Opinion issued in International Application No. PCT/US2018/036508, dated Aug. 30, 2018 (9 pages). |
International Search Report and Written Opinion issued in International Application No. PCT/US2020/047324, dated Oct. 4, 2020 (15 pages). |
International Search Report and Written Opinion issued in International Application No. PCT/US2021/15708, dated May 7, 2021 (10 pages). |
International Search Report and Written Opinion of the International Searching Authority dated Aug. 30, 2018 for International Application No. PCT/US2018/036508 (14 Pages). |
Irish Medicines Board “Viaspan” Summary of Product Characteristics available online at <https://www.hpra.ie/img/.../LicenseSPC_PA0002-075-001_21112012111041.pdf>, Nov. 21, 2012 (6 Pages). |
LifePort Brochure, Organ Recovery Systems obtained from www.organ-recovery.com. |
Organ Recovery Systems, Inc., LifePort Brochure, www.organ-recovery.com retrieved Aug. 29, 2012 (12 pages). |
Steinbrook, The New England Journal of Medicine, Organ Donation after Cardiac Death. July 9, 2007 (5 pages). |
Tolstykh, et al., Novel protable hypothermic pulsatile perfusion preservation technology: Improved viability and function of rodent and canine kidneys, Ann Transplant, 2010; 15(3):1-9. |
Tolstykh, et al., Perfusion Preservation of Rodent Kidneys in a Portable Preservation Device Based on Fuidics Technology, May 15, 2002, vol. 73, No. 9, 1508-1526. |
Wandall, et al., Galactosylation does not prevent the rapid clearance of long-term 40C-stored platelets, Blood, 2008; 111(6):3249-3256. |
Weegman, et al., Continuous Real-time Viability Assessment of Kidneys Based on Oxygen Consumption, Transplant Proc. 2010; 42(6):2020-2023. |
Number | Date | Country | |
---|---|---|---|
20210337781 A1 | Nov 2021 | US |
Number | Date | Country | |
---|---|---|---|
62650610 | Mar 2018 | US | |
62584330 | Nov 2017 | US | |
62516581 | Jun 2017 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 16002795 | Jun 2018 | US |
Child | 17378233 | US |